GO:0006012 galactose metabolic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006012 galactose metabolic process describes the chemical reactions and pathways involving galactose, an aldohexose widely distributed in combined form in plants, animals and microorganisms.
• Galactose is essential for glycosylation of proteins and lipids, and its metabolism intersects with glucose metabolism, energy production and congenital disorders of glycosylation [1,2].
• The Leloir pathway, comprising GALK1, GALT and GALE, is the main route for galactose catabolism in humans; defects cause galactosemia and related metabolic diseases [2,8].
• Galactose metabolism is critical in perinatal nutrition and intestinal absorption, with glucose-galactose malabsorption caused by SLC5A1 mutations [3,4,7].
• Enzymatic biosynthesis of D-galactose derivatives is an emerging biotechnological application of galactose metabolic enzymes.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of galactose metabolic genes in disease and glycosylation research.
Description
Galactose metabolic process (GO:0006012) encompasses the chemical reactions and pathways involving galactose, an aldohexose that is widely distributed in combined form in plants, animals and microorganisms as a constituent of oligo- and polysaccharides, galactolipids, and as its glucoside in lactose and melibiose. This process is fundamental to energy metabolism, protein and lipid glycosylation, and the synthesis of complex carbohydrates [1,2]. In humans, galactose is primarily derived from dietary lactose, which is hydrolyzed to glucose and galactose in the intestine, and is then metabolized predominantly via the Leloir pathway [2,7]. Research into galactose metabolic process is driven by its clinical relevance: inherited defects in galactose metabolism cause galactosemia, a potentially life-threatening disorder if untreated, and congenital disorders of glycosylation (CDG) that affect multiple organ systems [1,2,6]. Moreover, galactose metabolism is exploited in biotechnology for the enzymatic synthesis of D-galactose derivatives, which have applications in food, pharmaceutical and cosmetic industries. Understanding the genes, enzymes and regulatory mechanisms of this pathway is therefore essential for both basic biology and translational medicine. This article provides a research-grade overview of GO:0006012, covering its definition, key genes, regulatory features, disease associations, and experimental models including CRISPR-based approaches. All statements are grounded in published literature to support researchers, clinicians and AI-driven knowledge systems.
galactose metabolic process At A Glance
| GO ID | GO:0006012 |
|---|---|
| GO term | galactose metabolic process |
| Ontology | biological_process |
| Synonym | galactose metabolism |
| Definition | The chemical reactions and pathways involving galactose, the aldohexose galacto-hexose. D-galactose is widely distributed in combined form in plants, animals and microorganisms as a constituent of oligo- and polysaccharides; it also occurs in galactolipids and as its glucoside in lactose and melibiose. |
| Major function | Energy production, glycosylation, and synthesis of complex carbohydrates |
| Key enzymes | GALK1, GALT, GALE (Leloir pathway) |
| Associated diseases | Galactosemia, congenital disorders of glycosylation, glucose-galactose malabsorption |
| Research relevance | Metabolic disorders, glycosylation biology, biotechnology |
What Is GO:0006012?
GO:0006012 galactose metabolic process is defined as the chemical reactions and pathways involving galactose, the aldohexose galacto-hexose. D-galactose is widely distributed in combined form in plants, animals and microorganisms as a constituent of oligo- and polysaccharides; it also occurs in galactolipids and as its glucoside in lactose and melibiose. This biological process includes the breakdown of galactose for energy, its interconversion with glucose derivatives, and its incorporation into glycoconjugates [1,2].
Why Is galactose metabolic process Important in Cell Biology?
Galactose metabolic process is critically important because it provides a major route for the utilization of dietary galactose and for the synthesis of glycoproteins and glycolipids, which are essential for cell recognition, signaling and structural integrity [1,2]. Defects in this pathway lead to severe human diseases, including classic galactosemia and congenital disorders of glycosylation, which can cause liver failure, neurological impairment and developmental delay [2,6,8]. Additionally, galactose metabolism is relevant to perinatal nutrition, as neonates have a high demand for galactose for glycosylation and energy. Understanding this process also enables biotechnological production of D-galactose derivatives for pharmaceutical and food applications.
• Provides essential energy and carbon for glycosylation reactions in all tissues.
• Defects cause galactosemia, a life-threatening disorder if untreated [2,8].
• Implicated in congenital disorders of glycosylation (CDG) with multisystem phenotypes.
• Critical for intestinal absorption of galactose; mutations in SLC5A1 cause glucose-galactose malabsorption [3,7].
• Perinatal galactose metabolism is developmentally regulated and essential for neonatal health.
• Enables enzymatic biosynthesis of D-galactose derivatives for industrial applications.
• Serves as a model for studying inborn errors of metabolism and dietary management.
• Links to cancer metabolism and neurodegeneration through glycosylation changes.
• Supports research on host-microbiome interactions via galactose-containing polysaccharides.
• Facilitates development of CRISPR-based therapies for metabolic disorders.
What Happens During galactose metabolic process?
Uptake and Phosphorylation of Galactose
In simple terms: Galactose enters cells and is immediately tagged with a phosphate group to keep it inside.
Galactose is absorbed from the intestine via sodium-dependent glucose transporters, primarily SGLT1 (SLC5A1), and then enters the bloodstream. Inside cells, galactose is phosphorylated by galactokinase (GALK1) to galactose-1-phosphate, a key step in the Leloir pathway [2,8]. This phosphorylation traps galactose intracellularly and prepares it for further metabolism.
Leloir Pathway Interconversion
In simple terms: A series of enzymes convert galactose into glucose derivatives that the cell can use for energy.
Galactose-1-phosphate is converted to UDP-galactose by galactose-1-phosphate uridylyltransferase (GALT), which transfers a uridine group from UDP-glucose, releasing glucose-1-phosphate [2,8]. UDP-galactose is then epimerized to UDP-glucose by UDP-galactose-4-epimerase (GALE), completing the Leloir pathway. These reactions allow galactose to enter glycolysis and glycosylation pathways.
Glycosylation and Complex Carbohydrate Synthesis
In simple terms: Galactose is attached to proteins and lipids to build important cellular structures.
UDP-galactose serves as a donor substrate for galactosyltransferases in the Golgi apparatus, which add galactose to glycoproteins and glycolipids. This glycosylation is essential for protein folding, cell adhesion, and signaling [1,2]. Defects in glycosylation lead to congenital disorders of glycosylation (CDG).
Alternative Catabolic Routes
In simple terms: Galactose can also be broken down through other minor pathways when the main route is blocked.
In addition to the Leloir pathway, galactose can be metabolized via the De Ley-Doudoroff pathway and other minor routes in some organisms, but in humans the Leloir pathway is predominant [1,2]. Accumulation of galactose-1-phosphate, as seen in galactosemia, can be toxic and is implicated in pathophysiology.
Regulation by Substrate Availability and Hormones
In simple terms: The speed of galactose processing adjusts based on diet and hormonal signals.
Galactose metabolism is regulated by dietary intake, developmental stage, and hormones such as insulin. Perinatal galactose metabolism is particularly important because neonates have high demands for galactose for glycosylation and energy. Enzyme expression levels of GALK1, GALT, and GALE are also modulated in response to metabolic needs.
Key Genes Involved in GO:0006012 galactose metabolic process
The following genes encode enzymes, transporters and regulatory proteins directly involved in galactose metabolic process (GO:0006012).
| Gene | Major Role | Research Relevance |
|---|---|---|
| GALK1 | Phosphorylates galactose to galactose-1-phosphate | Mutations cause galactokinemia; target for metabolic studies [2,8] |
| GALT | Converts galactose-1-phosphate to UDP-galactose | Defects cause classic galactosemia; key disease gene [2,8] |
| GALE | Epimerizes UDP-galactose to UDP-glucose | Defects cause epimerase deficiency galactosemia |
| SLC5A1 | Intestinal sodium-dependent glucose/galactose transporter | Mutations cause glucose-galactose malabsorption [3,7] |
| SLC2A2 | Facilitative glucose transporter (GLUT2) | Facilitates galactose transport in liver and kidney |
| SLC2A5 | Fructose transporter (GLUT5) | May transport galactose in some tissues |
| HK1 | Hexokinase 1, phosphorylates galactose | Alternative phosphorylation route |
| B4GALT1 | Beta-1,4-galactosyltransferase 1 | Adds galactose to glycoconjugates; glycosylation studies |
| B4GALT2 | Beta-1,4-galactosyltransferase 2 | Glycosylation of proteins and lipids |
| B3GALT1 | Beta-1,3-galactosyltransferase 1 | Synthesis of galactose-containing glycans |
| B3GALT2 | Beta-1,3-galactosyltransferase 2 | Glycosphingolipid synthesis |
| A4GALT | Alpha-1,4-galactosyltransferase | Globotriaosylceramide synthesis; disease relevance |
| UGP2 | UDP-glucose pyrophosphorylase 2 | Provides UDP-glucose for GALT reaction |
| PGM1 | Phosphoglucomutase 1 | Interconverts glucose-1-phosphate and glucose-6-phosphate |
| G6PD | Glucose-6-phosphate dehydrogenase | Links galactose metabolism to pentose phosphate pathway |
| AKR1B1 | Aldose reductase | Converts galactose to galactitol; implicated in diabetic complications |
| SORD | Sorbitol dehydrogenase | Metabolizes galactitol; polyol pathway |
| TPI1 | Triosephosphate isomerase 1 | Glycolytic enzyme downstream of galactose metabolism |
How Is galactose metabolic process Regulated?
Galactose metabolic process is regulated at multiple levels. Dietary galactose availability influences enzyme expression, particularly in the liver and intestine. Perinatal galactose metabolism is developmentally regulated, with high demand for galactose for glycosylation in neonates. Hormonal signals such as insulin can modulate the activity of key enzymes like GALK1 and GALT. Additionally, feedback inhibition by downstream metabolites, such as UDP-glucose and UDP-galactose, fine-tunes flux through the Leloir pathway. Inborn errors of metabolism, such as galactosemia, result from mutations in GALT, GALK1 or GALE, leading to accumulation of toxic intermediates like galactose-1-phosphate.
galactose metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GALT | Classic galactosemia | Knockout or point-mutation in cell lines (e.g., HepG2) [2,8] |
| GALK1 | Galactokinemia | Knockout in HEK293 or patient-derived iPSCs |
| GALE | Epimerase deficiency galactosemia | Knock-in of patient mutations in cell models |
| SLC5A1 | Glucose-galactose malabsorption | Knockout in intestinal organoids [3,7] |
| B4GALT1 | CDG and cancer glycosylation | Overexpression or knockout in cancer cell lines [1,6] |
Classic Galactosemia
Classic galactosemia is an autosomal recessive disorder caused by mutations in GALT, leading to deficient galactose-1-phosphate uridylyltransferase activity [2,8]. Affected infants present with failure to thrive, jaundice, liver failure, and increased risk of sepsis after galactose ingestion. Accumulation of galactose-1-phosphate is considered a key pathogenic factor, causing cellular toxicity. Early diagnosis and dietary galactose restriction are essential, but long-term complications including neurological deficits and ovarian dysfunction may persist.
Glucose-Galactose Malabsorption
Glucose-galactose malabsorption is caused by mutations in SLC5A1, which encodes the intestinal sodium-dependent glucose transporter SGLT1 [3,7]. This defect impairs intestinal absorption of glucose and galactose, leading to severe osmotic diarrhea in neonates. Treatment involves a glucose-galactose-free diet, which resolves symptoms. This condition highlights the critical role of galactose transport in overall galactose metabolism.
Congenital Disorders of Glycosylation (CDG)
Defects in galactose metabolism can lead to congenital disorders of glycosylation, a group of rare inherited diseases affecting protein and lipid glycosylation. CDG often presents with multisystem involvement, including neurological impairment, liver dysfunction, and immune deficiency. Therapeutic approaches include dietary supplementation with galactose or other monosaccharides, though efficacy varies. Research into CDG has advanced through CRISPR-based disease models.
Galactose and Cancer Metabolism
Altered galactose metabolism and glycosylation are increasingly recognized in cancer, where changes in galactosyltransferase expression affect tumor cell adhesion, signaling, and metastasis. Targeting galactose metabolic enzymes is being explored as a therapeutic strategy, though further research is needed.
From galactose metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GALT loss cause galactose-1-phosphate accumulation? | GALT knockout in HepG2 cells [2,8] |
| Can a specific point mutation in GALE restore enzyme activity? | Point-mutation knock-in in HEK293 cells |
| How does SLC5A1 deficiency affect galactose uptake? | SLC5A1 knockout in Caco-2 cells [3,7] |
| What is the role of B4GALT1 in glycosylation? | B4GALT1 overexpression in HeLa cells |
| Can CRISPR correct a galactosemia-causing mutation? | Knock-in of wild-type GALT in patient iPSCs |
| How does galactose metabolism affect cancer cell growth? | GALK1 knockout in breast cancer cell lines |
How to Study the galactose metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Levels of galactose, galactose-1-phosphate, UDP-galactose | Diagnosis of galactosemia; flux analysis [2,8] |
| Enzyme activity assay | GALK1, GALT, GALE activity | Functional validation of mutations [2,8] |
| Lectin blotting | Glycosylation status of proteins | CDG research |
| CRISPR knockout screening | Gene essentiality in galactose metabolism | Identification of novel regulators |
| RNA-seq | Transcriptional changes in galactose metabolic genes | Response to dietary or genetic perturbations |
| Proteomics | Protein expression of Leloir pathway enzymes | Biomarker discovery |
| Isotope tracing | Metabolic flux through galactose pathway | Cancer metabolism studies |
| Organoid culture | Intestinal galactose absorption | Glucose-galactose malabsorption modeling [3,7] |
Metabolic Flux Analysis
Metabolic flux analysis using stable isotope-labeled galactose (e.g., 13C-galactose) coupled with mass spectrometry allows quantification of pathway activity and intermediate levels [1,2]. This method is essential for studying enzyme deficiencies and the impact of genetic variants.
Enzyme Activity Assays
Enzyme activity assays for GALK1, GALT, and GALE are used to diagnose galactosemia and to assess the functional impact of mutations [2,8]. These assays typically measure the conversion of substrates to products using spectrophotometric or radiometric methods.
Glycosylation Analysis
Glycosylation analysis by mass spectrometry, lectin blotting, or HPLC is used to evaluate the incorporation of galactose into glycoproteins and glycolipids [1,6]. These methods are critical for studying CDG and the role of galactose metabolism in glycosylation.
CRISPR Screening and Functional Genomics
CRISPR library screening enables systematic knockout of genes involved in galactose metabolism to identify essential genes and pathways. This approach can uncover novel regulators and therapeutic targets.
How CRISPR Can Be Used to Study GO:0006012 galactose metabolic process
Knockout
CRISPR knockout of GALT, GALK1, or GALE in cell lines such as HepG2 or HEK293 creates models of galactosemia to study disease mechanisms and test therapies [2,8]. Knockout of SLC5A1 in intestinal organoids models glucose-galactose malabsorption [3,7].
Point Mutation
CRISPR point mutation knock-in allows precise introduction of patient-specific mutations, such as common GALT variants, to study their functional impact on enzyme activity and glycosylation [2,6]. This approach is valuable for genotype-phenotype correlation.
Knock-in
Knock-in of wild-type or tagged versions of galactose metabolic genes (e.g., GALT-GFP) enables visualization and quantification of protein localization and dynamics [1,6]. It also facilitates correction of disease-causing mutations in patient-derived iPSCs.
Overexpression
Overexpression of galactose metabolic enzymes, such as B4GALT1 or GALE, in cell lines is used to study their role in glycosylation and to produce recombinant glycoproteins with defined glycan structures. This approach is also used in biotechnology for D-galactose derivative synthesis.
How EDITGENE Supports galactose metabolic process Research
Researchers studying galactose metabolic process-related genes often need to determine whether a candidate gene is causally involved in disease or glycosylation biology. EDITGENE provides a comprehensive suite of CRISPR services to create precise cellular models for functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for galactose metabolic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| GALK1 Knockout HEK293 Cell Line | EDJ-KQ3079 | Human | 2584 | Details Get a Quote |
| SLC35A2 Knockout HEK293 Cell Line | EDJ-KQ3494 | Human | 7355 | Details Get a Quote |
| GALM Knockout HEK293 Cell Line | EDJ-KQ3511 | Human | 130589 | Details Get a Quote |
| GALE Knockout HEK293 Cell Line | EDJ-KQ4670 | Human | 2582 | Details Get a Quote |
| GALK2 Knockout HEK293 Cell Line | EDJ-KQ4678 | Human | 2585 | Details Get a Quote |
| CHST1 Knockout HEK293 Cell Line | EDJ-KQ6274 | Human | 8534 | Details Get a Quote |
| GALT Knockout HEK293 Cell Line | EDJ-KQ17877 | Human | 2592 | Details Get a Quote |
| GALK1 Knockout HeLa Cell Line | EDJ-KQ22996 | Human | 2584 | Details Get a Quote |
| GALM Knockout HCT 116 Cell Line | EDJ-KQ23951 | Human | 130589 | Details Get a Quote |
| GALK1 Knockout A-549 Cell Line | EDJ-KQ24371 | Human | 2584 | Details Get a Quote |
| GALK1 Knockout HCT 116 Cell Line | EDJ-KQ24372 | Human | 2584 | Details Get a Quote |
| SLC35A2 Knockout A-549 Cell Line | EDJ-KQ25287 | Human | 7355 | Details Get a Quote |
| SLC35A2 Knockout HCT 116 Cell Line | EDJ-KQ25288 | Human | 7355 | Details Get a Quote |
| SLC35A2 Knockout HeLa Cell Line | EDJ-KQ25289 | Human | 7355 | Details Get a Quote |
| GALM Knockout A-549 Cell Line | EDJ-KQ25326 | Human | 130589 | Details Get a Quote |
Displaying Records 1 To 15 Of 28 Records
Frequently Asked Questions About galactose metabolic process
What is GO:0006012 galactose metabolic process?
GO:0006012 is a Gene Ontology biological process term defined as the chemical reactions and pathways involving galactose, an aldohexose widely distributed in combined form in plants, animals and microorganisms.
What genes are involved in galactose metabolic process?
Key genes include GALK1, GALT, GALE, SLC5A1, and various galactosyltransferases such as B4GALT1 [1,2,7].
What is the Leloir pathway?
The Leloir pathway is the main route for galactose catabolism in humans, involving GALK1, GALT, and GALE enzymes [2,8].
What diseases are associated with galactose metabolic process?
Diseases include classic galactosemia, glucose-galactose malabsorption, and congenital disorders of glycosylation [2,3,6].
How is galactose metabolism studied in the lab?
Common methods include enzyme activity assays, LC-MS metabolomics, glycosylation analysis, and CRISPR screening [1,2,6].
What is the role of galactose in glycosylation?
Galactose is a key component of glycoproteins and glycolipids, added by galactosyltransferases in the Golgi.
Can CRISPR be used to model galactosemia?
Yes, CRISPR knockout or point mutation of GALT in cell lines creates models for galactosemia research [2,6].
What is glucose-galactose malabsorption?
It is a disorder caused by mutations in SLC5A1, leading to impaired intestinal absorption of glucose and galactose [3,7].
How is galactose metabolism regulated?
It is regulated by dietary intake, developmental stage, hormones, and feedback inhibition by metabolites [2,4].
What are the biotechnological applications of galactose metabolism?
Enzymes of galactose metabolism are used for enzymatic biosynthesis of D-galactose derivatives for food and pharmaceutical industries.
Conclusion
Galactose metabolic process (GO:0006012) is a fundamental biological pathway with critical roles in energy metabolism, glycosylation, and human disease. Understanding its genes, regulation, and disease associations is essential for developing diagnostics and therapies for galactosemia, CDG, and related disorders. CRISPR-based models and advanced analytical methods continue to drive discoveries in this field, offering new opportunities for therapeutic intervention and biotechnology.
References
- 1. Conte F et al.. 2021. Galactose in human metabolism, glycosylation and congenital metabolic diseases: Time for a closer look.. Biochim Biophys Acta Gen Subj 1865(8):129898 PMID: 33878388
- 2. Coelho AI et al.. 2015. Galactose metabolism and health.. Curr Opin Clin Nutr Metab Care 18(4):422-7 PMID: 26001656
- 3. Abraham JM et al.. 1967. Glucose-galactose malabsorption.. Arch Dis Child 42(226):592-7 PMID: 6073825
- 4. Kliegman RM et al.. 1985. Perinatal galactose metabolism.. J Pediatr 107(6):831-41 PMID: 3906069
- 5. Liu J et al.. 2024. Enzymatic biosynthesis of D-galactose derivatives: Advances and perspectives.. Int J Biol Macromol 267(Pt 2):131518 PMID: 38615865
- 6. Brasil S et al.. 2018. CDG Therapies: From Bench to Bedside.. Int J Mol Sci 19(5) PMID: 29702557
- 7. Wright EM et al.. 2003. Intestinal absorption in health and disease--sugars.. Best Pract Res Clin Gastroenterol 17(6):943-56 PMID: 14642859
- 8. Gitzelmann R. 1995. Galactose-1-phosphate in the pathophysiology of galactosemia.. Eur J Pediatr 154(7 Suppl 2):S45-9 PMID: 7671964
